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Introduction
The term behavioural and psychological symp-
toms of dementia (BPSD; also termed neuropsy-
chiatric symptoms) describes the heterogeneous 
group of symptoms and signs of disturbed per-
ception, thought content, mood or behaviour that 
frequently occur in patients with dementia.1,2 
Throughout the course of their dementia, the vast 
majority of patients will develop one or more 
BPSD.1–6 BPSD can have serious consequences. 
They are associated with worsening cognition and 
progression to more severe stages of dementia.7 
BPSD also lead to individual suffering and impact 
the caregiver burden.8 Furthermore, they increase 
the risk for secondary complications such as falls 
and fractures leading to emergency room admis-
sions,9 and ultimately institutionalization.10,11 
Finally, BPSD result in higher costs of therapy 
and caregiving.12,13
The treatment of patients with BPSD can be chal-
lenging for physicians and healthcare teams. The 
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etiopathogenesis of BPSD is often complex, with 
multiple contributing direct factors and indirect 
mediators. Biological factors (e.g. brain changes, 
comorbidities, medication) may interact with psy-
chological (e.g. personal life history, personality) 
or social (support network, living arrangements) 
aspects. Consequently, treatment should be 
guided by a comprehensive etiopathogenetic 
assessment. Currently, there is limited evidence 
for symptomatic treatments and the available evi-
dence-based options are only moderately effec-
tive. Psychosocial, that is non-pharmacological, 
approaches should be considered the mainstay of 
therapy and are complemented by psychotropic 
medication only if unavoidable. Ideally, the avail-
able treatment algorithms are used to devise an 
individualized treatment plan informed by a mul-
tifaceted understanding of the patient’s situation, 
clinical experience and expert knowledge.
Clinical presentation of BPSD
The clinical presentations of BPSD include apa-
thy, depression, anxiety, delusions, hallucinations, 
sexual or social disinhibition, sleep–wake cycle 
disturbances, aggression, agitation and other 
behaviours considered inappropriate.14 There are 
several instruments to systematically assess the 
presence and severity of BPSD,15 among which 
the Neuropsychiatric Inventory (NPI)16 and 
Behavioral Pathology in Alzheimer’s Disease 
Rating Scale (BEHAVE-AD)17 are recom-
mended.18 Some BPSD tend to cluster together, 
usually into four clusters – that is, the affective, 
psychotic, hyperactive and apathetic clusters.1,19 
In a population-based study, the cumulative inci-
dence of having one or more NPI-measured 
BPSD from the onset of cognitive symptoms was 
80%,20 indicating that occurrence of BPSD has to 
be expected throughout the course of dementia. 
Apathy, depression, anxiety and agitation were 
found to be the most frequent forms of BPSD.2,20,21 
However, a recent systematic review revealed sub-
stantial variation in the reported prevalence, inci-
dence and longitudinal course between different 
studies.22 In an individual patient, the type and 
severity of BPSD tend to change over time, but 
some forms such as wandering seem to be more 
persistent.22 Overall, the ‘natural course’ of BPSD 
over time is still largely unknown.
Depression
Most patients with dementia have depressive 
symptoms and signs at some point in time over 
the course of dementia (nearly 80% over the past 
5 years). Some patients may present with a major 
depressive disorder (10–20%).1 A history of 
depressive disorder is likely to increase the risk of 
major depressive disorder during dementia. 
Insomnia, changes in circadian rhythm and anxi-
ety may accompany depressive symptoms. 
Abnormalities in the serotonin, dopamine or epi-
nephrine systems, frontal atrophy, and amygdala 
reactivity may be some of the neurobiological 
underpinnings of depressive features.
Hallucinations
Another condition that should be considered is 
the Charles Bonnet syndrome, which is due to 
an eye disease. Visual hallucinations in Charles 
Bonnet syndrome are usually of short duration 
and patients are aware that they are not real; 
these hallucinations are often well tolerated by 
the patient and therefore may not need treat-
ment other than that prompted by the underly-
ing eye disease. In some instances, carbamazepine 
may be useful.23 Auditory hallucinations must 
evoke an underlying psychotic state not primar-
ily explained by dementia, and usually need 
treatment.
Agitation
In an inpatient clinical setting, agitation is often 
the most challenging BPSD since it may severely 
disrupt patient care. Hence, most treatment trials 
for BPSD have been performed for agitation. 
Agitation refers to an ill-defined spectrum of 
aberrant hyperactive motor behaviours (such as 
wandering, leaving home) and physically or ver-
bally aggressive behaviours such as rejection of 
care. Only recently a provisional consensus defi-
nition has been suggested for agitation in cogni-
tive disorders.24 Beyond the behavioural 
phenotype, this new definition emphasizes the 
emotional distress and excess disability that is 
associated with agitation. Agitation may worsen 
during the evening hours, a phenomenon referred 
to as ‘sundowning’.25
Delusions
Since delusions in dementia are found to some-
times correspond to reality or to be neither 
incorrigible nor held with absolute certainty, 
they may not represent psychotic symptoms in a 
narrow sense and should certainly not preclude 
the attempt to understand their meaning.26  
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In terms of content, delusions in dementia are 
frequently persecutory in nature or revolve 
around theft – that is, lost objects,27 danger, 
abandonment and the idea that one’s house is 
not one’s home.26 Notably, only about half of 
the cases of delusions appear to lead to discom-
fort and are associated with behavioural distur-
bances.28 A frequent subtype of delusions in 
dementia is the misidentification syndromes in 
which a patient consistently misidentifies per-
sons, places, objects or events (e.g. Capgras 
syndrome).29 Sensory impairment is widely con-
sidered a contributory factor in the development 
of certain delusions in dementia, most obviously 
in cases of Charles Bonnet syndrome in the con-
text of visual impairment.
Apathy
Apathy is usually defined as loss of motivation 
and decreased interest in daily activities.30 In the 
most severe forms, the affected patients may be 
unable to initiate almost any kind of directed 
activity, thus spending most of the day in bed or 
sitting in a chair. Apathy is one of the most fre-
quent forms of BPSD and is associated with 
poor prognosis and increased mortality.31,32 
However, apathy rarely leads to hospital admis-
sions since it is not usually as disruptive for car-
egivers as other BPSD.
Sleep problems and disturbances of circadian 
rhythms
Sleep problems are both risk factors and frequent 
symptoms of dementias and may also arise from 
comorbidities.33,34 Sleep problems are a major 
contributor to caregiver burden. Even though the 
clinical need for effective treatments is high, the 
evidence base for treatments is limited.35 In 
dementia with Lewy bodies (DLB), REM (rapid 
eye movement) sleep behaviour disorder (RBD) 
can be an early sign of the disease, with daytime 
fluctuations of attention, greater number of day-
time naps and longer night sleeps.36,37 RBD can 
also be seen in other synucleopathies such as 
Parkinson’s disease and multiple system atrophy. 
In frontotemporal dementia (FTD), RBD is rare 
but may be confused with excessive nocturnal 
activity due to disturbed circadian rhythmicity.38
Etiopathogenesis of BPSD
More often than not the etiopathogenesis of 
BPSD is complex and multifactorial.1 For the 
sake of didactic simplicity and practicability, the 
causative and contributing factors can be divided 
into biological, psychological and social or envi-
ronmental factors (Figure 1).
Based on this perspective, a model for etiopatho-
genetic treatment of BPSD can be derived.
Figure 1. Simplified etiopathogenetic model of BPSD.
m, modifiable; pm, potentially modifiable; u, unmodifiable.
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Biological perspective
Brain lesions and type of dementia. Dementia-
related brain lesions and changes in neurotrans-
mission have been linked to specific BPSD.1 Their 
effect may be moderated by other biological fac-
tors such as comorbidity or treatment-related fac-
tors, as well as the individual’s genetic make-up.
In the course of Alzheimer’s disease (AD), psy-
chotic symptoms were found to be associated 
with neuronal loss in several brain regions, includ-
ing the hippocampus, parahippocampal gyrus 
and various brain stem nuclei.39 In mixed (vascu-
lar and AD) dementia, vascular factors may trig-
ger hallucinations, illusions, anxiety, dysphoria, 
aggression and delirium.39–41
Besides the aphasic forms, FTD is defined by 
behavioural features (bv-FTD or behavioural var-
iant of FTD). These features are present from the 
early stages of the disorder and include loss of 
interest and apathy, as well as disinhibition, 
including inappropriate sexual behaviour and 
impulsive behaviours that are more frequent than 
in other dementias.39 Both sporadic and familial 
forms of FTD have been described.42,43 Similar to 
AD, a number of neurotransmitter and cortico-
limbic changes have been linked to behavioural 
disruptions in FTD.1,42,44 Clearly, FTD is an 
important differential diagnosis, particularly in 
the early dementia stages. It is different from the 
frontal variant of AD,45 and BPSD in FTD are 
probably less amenable to efficient treatment 
than in other forms of dementia.
Many neuroanatomical studies have been con-
ducted that link BPSD to dementia-related brain 
lesions. For example, apathy was associated with 
hypoperfusion in the anterior cingulate cortex and 
fronto-subcortical structures,1,46 giving rise to a 
disconnection model of apathy between the pre-
frontal cortex and the mediodorsal and anterior 
thalamic nuclei.47 However, hypoperfusion in 
frontal or temporal lobes was also found to corre-
late with aggression and psychosis.1 A variety of 
functional and structural parameters including, for 
example, white matter changes,48 atrophy patterns 
and vascular damage contribute to BPSD.48,49
Changes in neurotransmission and neuromodu-
lation. Changes in neurotransmission and neu-
romodulation have been found to correlate with 
BPSD. In AD, changes in cholinergic activity in 
the frontal and temporal cortices may be linked 
to aberrant motor activity and aggressive 
behaviour.50,51 Visual hallucinations in DLB 
seem to be linked with cholinergic deficits in the 
temporal cortex.50 In AD, aggression was 
reported to be related to reduced dopamine con-
centration in the temporal cortex.44 Decreased 
norepinephrine neurons in the locus coeruleus 
are accompanied by aggressive behaviour.1,52 
Similarly, apathy was correlated with dopami-
nergic dysfunction in AD.31,53,54 Serotonin 
concentration correlated positively with aggres-
siveness, depressed mood, anxiety, agitation and 
restlessness.1 Interestingly, serotonin and, thus, 
SSRIs, may improve hippocampal neurogene-
sis,55 and synaptic plasticity and survival of neu-
rons are linked to the glutamatergic pathway.1,56,57 
Severe glutamate loss in AD may result in psy-
chotic symptoms. Significant GABA decrease in 
the frontal and temporal cortex and high GABA 
plasma concentration were found in severe AD 
that correlated with depression and apathy.1 As 
drugs acting on the above-mentioned neu-
rotransmitter systems are legion, it is evident 
that many of them can either cause or favour the 
development of BPSD58 or, on the contrary, have 
a potentially positive influence on them. Further 
pathway disorders related to neuromodulator 
and neuroendocrine systems have been proposed 
as correlates of BPSD, as well as circadian 
rhythms and sleep disorders,1,59,60 including 
those of the hypothalamic–pituitary–adrenal axis 
or the homocystein metabolism.61
A number of findings suggest a genetic vulnera-
bility for BPSD, though this field of research is 
still in its infancy. As an example, AD subjects 
who are ApoEε4 carriers had more delusions and 
agitation/aggressive behaviours than non-ApoEε4 
carriers.62 Given the implication in BPSD of neu-
rotransmitter changes, it may come as no surprise 
that specific polymorphisms may predispose to 
BPSD.62–64
Physical disorders and pain. Physical disorders 
are often a central element in the understanding 
of BPSD and must be evaluated and treated 
accordingly.1,6,58,65 Among the most frequent 
somatic causes of BPSD are pain, infections, 
electrolyte imbalances or metabolic disorders, 
urinary retention, constipation, cerumen and 
others. Any of these may cause BPSD and a 
thorough medical examination is therefore a 
requirement. Especially pain often leads to 
BPSD of various types, such as insomnia, aggres-
siveness or agitation.66 Looking for pain-induc-
ing factors and eliminating them is pivotal, as 
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pain is too often undetected and therefore 
undertreated in people with dementia.
Psychological and environmental perspective
Considering BPSD as the result of stressors com-
bined with variable degrees of vulnerability, it is 
easy to imagine a host of psychological and sys-
temic factors (personality, environmental ele-
ments both physical and emotional that contribute 
to the occurrence of BPSD).
Personality traits. Personality changes occur 
when dementia develops. In AD, a predictable 
change seems to occur independently of the pre-
vious personality, in that neuroticism usually 
increases while extraversion, openness and con-
scientiousness tend to decrease, with agreeability 
remaining more stable.67 Furthermore and apart 
from its obvious face validity, there is increasing 
evidence that our personality – what we are as 
persons – contributes to the clinical expression of 
dementia. Thus, some personality traits may 
favour, or on the contrary protect against, BPSD. 
Thus, in AD, increased neuroticism as a premor-
bid personality trait may be associated with a 
higher risk for depression,1,65,68,69 and even be a 
risk factor for cognitive decline and AD.70,71 
Patients who have been suspicious or aggressive 
before dementia starts are more likely to have 
BPSD than those without these traits.1,69 How-
ever, such correlations have not always been 
found68 and one of the more significant limita-
tions of most of the studies currently available is 
the use of retrospective personality ratings, sub-
jecting their findings to possible inaccuracies. 
Psychiatric diseases may be risk factors for 
dementia as this has been established for depres-
sion and for BPSD.72
Life events. Stressful life events in childhood or 
adulthood may favour BPSD in dementia 
through, among other etiopathogenic lines, 
increased vulnerability related to hippocampal 
hypotrophy and behavioural inhibition or inse-
cure attachment.56,73–75 Thus, overt attachment 
behaviour towards a family member or stranger 
was pronounced in old nursing home residents 
depending on the degree of cognitive impairment, 
suggesting that dementia eroded feelings of secu-
rity and activated attachment behaviours.76,77 
Securely attached individuals with dementia dis-
played more positive affect than avoidantly 
attached individuals.78
Environmental risks. Environmental factors, both 
physical and social, are likely to precipitate or buffer 
BPSD. Thus, lower levels of BPSD are associated 
with well-being of nursing home residents, which is 
in turn related to environmental characteristics 
such as unobtrusive safety features, variety of spaces 
in environments with calm, single rooms available, 
small facility size, and optimization of levels of stim-
ulation, taking into account the capacities of each 
patient.1 Similarly, caregiver distress can exacerbate 
BPSD and family discord or altered communica-
tion in the family need to be assessed.79,80
Treatment
The treatment of BPSD is often highly challeng-
ing due to the complex etiopathogenesis of the 
symptoms and signs and the multi-morbidity of 
patients. BPSD management requires both a 
patient-centred and caregiver-centred focus and 
interventions to provide comfort to patients and 
alleviate caregiver burden are indispensable. 
Treating concomitant somatic diseases can 
reduce BPSD.6 Effective pain management is 
part of a successful BPSD treatment.81 Most 
expert recommendations and guidelines prefer 
non-pharmacological interventions as the first-
line approach.6,82,83 Although the evidence for 
most non-pharmacological strategies is weak, 
their efficacy is supported by long-standing clini-
cal experience. Pharmacotherapy for BPSD is 
frequently provided, but it carries the risk of 
serious side-effects. Therefore, non-pharmaco-
logical therapies are considered the first choice 
and should also be continued when pharmaco-
therapy is necessary. In order to measure treat-
ment effects, frequency and severity of BPSD 
should be quantified at baseline, possibly using a 
validated scale or questionnaire, such as the 
NPI16 or BEHAVE-AD.17,18 Moreover, several 
algorithms have been published to guide the 
diagnostic and therapeutic process for BPSD.14 
We suggest using the simplified BPSD-DATE 
algorithm (describe and measure, analyse, treat, 
evaluate; see Figure 2).
Non-pharmacological approaches
Due to the heterogeneous nature of non-pharma-
cological interventions, study designs vary widely 
in this area and call the generalizability of their 
results into question. Compared to pharmaco-
logical treatments of BPSD, the evidence base is 
much more limited. As of yet, it remains unclear 
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whether or not heterogeneous non-pharmacolog-
ical interventions are efficacious due to a com-
mon active but non-specific ingredient such as 
positive human interaction. At this point, the best 
scientific evidence exists for the use of home-
based behavioural management techniques, car-
egiver-based interventions or staff training in 
communication skills, person-centred care, 
dementia care mapping against agitation84,85 and 
music therapy against agitation and anxiety.84
Psychosocial interventions. Psychoeducation for 
patients and caregivers can reduce BPSD.6,86–88 
Multi-component single and group session pro-
grammes are effective if they focus on stressful 
events, provide both information about the disease 
and assistance, and allow for exchange on experi-
ences as to how to deal with daily problems. Group 
sessions are more disburdening for caregivers 
when they include training in behavioural man-
agement techniques.87,88 Coping strategy-based 
family carer therapy and tailored activities for peo-
ple with dementia and their caregivers were found 
to improve quality of life of people with dementia 
living at home.88 Psychoeducational interventions 
may be accompanied by social counselling, orga-
nizing assistance and supporting patients and 
caregivers. Psychosocial interventions, in general, 
decrease caregiver depression and can help delay 
the institutionalization of patients.89
Nursing care. The need-driven dementia- 
compromised behaviour model (NDB) can help 
understand BPSD as a dysfunctional expression 
of needs.90 Based on this model, behavioural 
analysis in nursing care may recognize the 
patient’s urgent needs and reveal their causes. 
Some factors causing BPSD, such as pain, 
hunger or thirst, can be satisfied immediately. 
However, personality characteristics and the 
biography of the patient, comorbidities and the 
lack of personal resources can complicate the 
course of the disease. The Serial Trial Interven-
tion, based on the NDB model, uses systematic 
serial assessments and sequential trials of treat-
ments to identify and treat unmet needs that may 
be the underlying cause of BPSD. It has been 
shown to reduce BPSD and the use of psychotro-
pic drugs.91 Special nursing care interventions 
targeting vocalization92 and sexual disinhibition93 
may be helpful to comfort patients.
Physical activity. Regular exercise improves physi-
cal fitness, behaviour, cognition and functioning 
in older people.94 There is strong evidence that 
regular physical activity improves physical, 
Figure 2. BPSD-DATE interventional algorithm.
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cognitive, functional and behavioural outcomes 
also in patients with dementia and can help 
reduce BPSD.94 Usually, training programmes 
are based on walking (mobility training) or they 
combine walking with different types of isotonic 
exercises.
Sensory stimulation and music therapy. Music 
therapy and multisensorial stimulation techniques 
such as snoezelen are effective in reducing agita-
tion and disruptive behaviour during sessions and 
immediately after the intervention.6,86 However, 
there is no evidence for long-term effects. Biogra-
phy-related music and combination with sensory 
stimulation seem to be more effective.
Reality orientation and cognitive stimulation ther-
apy. These interventions are based on the idea that 
a better orientation in daily life to persons, time or 
surroundings can improve BPSD.86 Reality orien-
tation therapy is more effective in combination 
with other techniques in improving mood and 
decreasing BPSD. Derived from reality orientation 
therapy, cognitive stimulation therapy addresses 
current problems in functioning using information 
processing.86 There are some immediate effects on 
BPSD, but the data are inconsistent.
Validation therapy. This patient-centred tech-
nique intends to resolve unfinished conflicts by 
encouraging and positively validating expression 
of feelings.86 There is some evidence that posi-
tively validating expression of feelings may reduce 
irritability.
Reminiscence therapy. Reminiscence therapy 
uses objects from daily life to stimulate memory 
and enable people to value their experiences.86 
This intervention can improve mood.
Psychotherapeutic interventions. Psychological 
therapies have been investigated in mild to mod-
erate dementia. The highest level of evidence of 
efficacy is available for cognitive behavioural tech-
niques.6,86,95,96 Focusing on daily problems, psy-
chotherapeutic interventions are more effective if 
caregivers are involved in the process. Combina-
tion with psychoeducation and family counselling 
improves effectiveness.96,97 Behavioural manage-
ment techniques improve depression, anxiety, 
aggression and agitation in dementia.86 The effect 
is significant and lasts for months. Since caregiv-
ers can also develop depression during the care 
process, they can also benefit from individual 
psychotherapy.
Psychopharmacotherapy
Since patients with dementia are particularly vul-
nerable to adverse effects of drugs, the indication 
for psychopharmacotherapy in BPSD has to be 
discussed very critically. Multi-morbidity and 
polypharmacy are interacting factors complicat-
ing the use of pharmacotherapy. Most drugs are 
not approved for BPSD and their use is therefore 
off-label. A detailed clinical and laboratory exam-
ination including history of medication and an 
electrocardiogram should precede psychophar-
macotherapy. Psychotropic medication use 
should be limited in time and stopped after a 
gradual reduction when BPSD improve. Drug 
metabolism is altered in elderly patients and com-
pared to younger patients they usually need lower 
doses of psychotropic drugs.
Antidementia drugs. There is some evidence that 
cholinesterase inhibitors and memantine may be 
useful in the management of BPSD.6,14,98–101 Cho-
linesterase inhibitors may improve affective fea-
tures in mild to moderate dementia. Cholinesterase 
inhibitors and memantine may be effective to treat 
BPSD. Indeed, donepezil may alleviate the follow-
ing BPSD in mild to moderate dementia: apathy, 
depression, tension, irritability. There are similar 
findings for galantamine and rivastigmine. How-
ever, treatment of agitation in AD by donepezil 
appears to be inefficient. In conclusion, cholines-
terase inhibitors have a certain efficacy on negative 
symptoms.6,102 Memantine may be more effective 
on positive symptoms including agitation, delu-
sions and hallucinations, as well as aggression in 
moderate to severe AD.6,102 However, more recent 
trials specifically designed for treatment of agita-
tion challenge these findings as they failed to dem-
onstrate a benefit.99,103,104 Finally, antidementia 
drugs may reduce the incidence of BPSD. There 
are also data that provide some evidence for the 
preventive efficacy of Ginkgo biloba extract EGb 
761® in the treatment of dementia patients with 
clinically relevant BPSD.105
Antidepressants. Depression and anxiety are 
among the most common BPSD and an effective 
antidepressive therapy in dementia can improve 
both cognition and affective symptoms as well as 
other forms of BPSD, such as agitation and 
aggressiveness.6,14,106 Tricyclic antidepressants are 
not recommended because of their anticholiner-
gic adverse events. SSRIs have reasonable tolera-
bility and favourable treatment response. In 
dementia, SSRIs (specifically citalopram) are as 
efficacious as atypical antipsychotics for treating 
Therapeutic Advances in Neurological Disorders 10(8)
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agitation.107 SSRIs can be associated with severe 
adverse effects such as QT-prolongation and 
hyponatraemia.
Antipsychotics. First, it is important to state that 
antipsychotics have not been approved for clinical 
use in dementia, except for risperidone, at least in 
some countries. Thus, clinicians ought to refer to 
their country’s legislation before introducing an 
antipsychotic drug to treat BPSD. Atypical anti-
psychotics such as risperidone and aripiprazole 
are among the most often (and probably too 
often) prescribed drugs in BPSD. They are effec-
tive in the treatment of psychotic symptoms, agi-
tation and aggression.2,14,108,109 Haloperidol may 
be considered in the treatment of delirium in 
dementia, but it is not recommended for a differ-
ent use in dementia. Haloperidol is only recom-
mended for delirium because of its high potential 
for side-effects. Adverse events associated with 
atypical antipsychotics include anticholinergic 
effects, orthostatic hypotension, seizures, meta-
bolic syndrome, weight gain, extrapyramidal 
symptoms, sedation and QT-prolongation. The 
increased mortality and the risk for cerebrovascu-
lar incidents have led to a black box warning for 
the use of antipsychotics in dementia. Antipsy-
chotics can be necessary and helpful in the treat-
ment of certain BPSD, but their use must be 
limited in time. Regular evaluations of risks and 
benefits are necessary throughout the course of 
the treatment.110 While the evidence on the effi-
cacy of quetiapine for BPSD is mixed, it is widely 
used clinically.111 Due to its favourable side-effect 
profile, particularly regarding extrapyramidal 
signs, quetiapine may be of particular value for 
BPSD, especially in patients with Parkinsonian 
features, despite conflicting evidence.112
Mood stabilizers. Although carbamazepine shows 
some benefit for agitation in dementia, mood sta-
bilizers are often associated with severe side-
effects.2,14,113 Thus, valproic acid is not 
recommended. There is some clinical experience 
and limited evidence for gabapentine and 
lamotrigine in the treatment of BPSD.
Benzodiazepines. Evidence for the efficacy of 
benzodiazepines in BPSD is lacking. Benzodiaze-
pines are associated with sedation, dizziness, falls, 
worsening cognition, respiratory depression, 
dependency and paradoxical disinhibition in the 
elderly. They are thus only recommended for the 
management of an acute crisis,6,14 if other meth-
ods fail. Their use must be limited in time and 
they should not be prescribed as hypnotics.
Other substances. Hypnotics such as zopiclone, 
zolpidem or zaleplone can have similar side-
effects as benzodiazepines.6 They are used for 
sleep disorders in dementia over a limited period 
of time and at small doses. Sedative antidepres-
sants such as trazodone seem to improve sleep 
duration. Melatonin and melatonin receptor ago-
nists can be effective in treating circadian sleep 
disorders.34,35
Biological therapies
Light therapy (in the morning) and light therapy 
in combination with melatonin (at bedtime) may 
be useful to treat sleep or circadian rhythm disor-
ders, ‘sundowning’ and day sleepiness,114 but 
sleep deprivation is not recommended in BPSD.6 
Indeed, there is a higher risk of agitation and 
other BPSD may appear due to insomnia.65
Electroconvulsive therapy may be helpful in indi-
vidual situations. Similarly, repeated transcranial 
magnetic stimulation may become a useful 
method, but the study of this method to treat 
BPSD is still in its infancy.
Conclusion
BPSD occur on an almost regular basis as demen-
tia evolves, regardless of the dementia type. BPSD 
are a heterogeneous group of symptoms and 
signs, but all of them may cause significant suffer-
ing in patients and caregivers. The causes of and 
risk factors for BPSD are multiple, even in a sin-
gle patient, with interacting biological, psycho-
logical and social/environmental causes and 
vulnerability factors. Taking a detailed history 
and performing a sound clinical investigation 
including the patient and their family or care team 
are essential. In order to arrive at an individual-
ized treatment plan, a therapeutic decision tree 
should be established taking into account the 
patient’s individual and their environmental risk 
profile. Psychosocial treatments are pivotal. 
Often, combining different non-pharmacological 
approaches precedes drug treatment that can be 
added if required. Consequently, an interven-
tional algorithm is proposed to take care of 
patients suffering BPSD (Figure 2). Regular 
assessments of the treatment plan and any pre-
scriptions must be carried out to detect signs of 
relapse and to stop any drug that has become 
inappropriate. Even with optimal management, 
BPSD will not disappear completely in some 
cases and will remain challenging for all involved 
parties.
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